Fresh analysis reveals that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise plans.
Research printed in a major medical journal points out that while obese individuals can lose about a fifth of their body weight while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these treatments need to be aware of the risk of rapid rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.
This pace of regain suggests a return to original mass within about 18 months.
Analyzing Treatments
The study, which examined dozens of studies involving thousands of participants, compared the outcomes of these new drugs with older methods.
The team note that people who shed pounds through dieting generally experience a less rapid creep back—around 100 grams monthly—once they finish.
Understanding the Fast Rebound
Nutrition scientists propose the mechanism of the drugs explains the accelerated weight return.
These medications copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone concentrations far above than the body's typical production may cause the system to produce less of its endogenous hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals argue that, due to the likelihood of weight regain, the treatment might need to be long-term.
This perspective is echoed by drug manufacturers, who state that the results "underscore the persistent nature of obesity," similar to managing conditions like hypertension.
Patient Testimonies
Users who have stopped the medication explain a sudden resurgence of appetite.
"I experienced something that goes on and I was suddenly extremely hungry," described an individual.
This challenge is worsened if users have not developed lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Figures indicate that a significant number of adults in the UK have used these injections in the past year, with demand continuing to grow.
- Adoption is higher among females compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, experts caution that while the jabs are powerful agents for shedding pounds, they are not a magic solution and maintained weight loss likely depends on combined lifestyle changes.
